Influence of chemical permeation enhancers on transdermal permeation of alfuzosin: An investigation using response surface modeling

Drug Development and Industrial Pharmacy

Volumn 37, Issue 4, 2011, Pages 465-474

  Pattnaik, Satyanarayan ^a   Swain, Kalpana ^a   Bindhani, Amarendra ^a   Mallick, Subrata ^b  

^a Department of Pharmaceutics   (India)

^b SIKSHA O ANUSANDHAN DEEMED TO BE UNIVERSITY   (India)

Author keywords

D optimal mixture design; permeation enhancers; polymeric system; preclinical studies; transdermal delivery

Indexed keywords

ALFUZOSIN; LAURIC ACID; OLEIC ACID; PENETRATION ENHANCING AGENT; PROPYLENE GLYCOL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG FORMULATION; DRUG PENETRATION; DRUG TRANSPORT; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; NONHUMAN; RABBIT; SKIN PERMEABILITY;

ADMINISTRATION, CUTANEOUS; ANIMALS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LAURIC ACIDS; MALE; OLEIC ACID; PROPYLENE GLYCOL; QUINAZOLINES; RABBITS; SKIN ABSORPTION;

EID: 79953244892     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.522192     Document Type: Article

References (30)

1. Prausnitz MR, Mitragotri S, Langer R. (2004). Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov, 3:115-24. (Pubitemid 38239773)
2. Williams AC, Barry BW. (2004). Penetration enhancers. Adv Drug Dev Rev, 56:603-18. (Pubitemid 38326936)
3. Mc Keage K, Plosker GL. (2002). Alfuzosin: A review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs, 62:633-53. (Pubitemid 34264032)
4. Roehrborn CG. (2001). Alfuzosin: Overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alphablocker. Urology, 58:55-63. (Pubitemid 34007600)
5. Pattnaik S, Swain K, Choudhury P, Acharya PK, Mallick S. (2009). Alfuzosin hydrochloride transdermal films: Evaluation of physicochemical, in vitro human cadaver skin permeation and thermodynamic parameters. Int Brazil J Urol, 35:716-29.
6. Melas VB. (2006). Functional approach to optimal experimental design. New York: Springer, 197-228.
7. Eriksson L, Johansson E, Wikstrom C. (1998). Mixture design: Design generation, PLS analysis and model usage. Chemomet Intell Lab Syst, 43:1-24. (Pubitemid 28481343)
8. Bodea A, Leucuta SE. (1997). Optimization of hydrophilic matrix tablets using a D-optimal design. Int J Pharm, 153:247-55. (Pubitemid 27308668)
9. Cornell JA. (1990). Designs models and the analysis of mixture data. 2nd ed. New York: John Wiley, 188-236.
10. Kligman AM, Christophers E. (1963). Preparation of isolated sheets of human stratum corneum. Arch Dermatol, 88:702-5.
11. Akomeah F, Nazir T, Martin GP, Brown MB. (2004). Effect of heat on the percutaneous absorption and skin retention of three model penetrants. Eur J Pharm Sci, 21:337-45. (Pubitemid 38156171)
12. Kumar MG, Lin S. (2008). Transdermal iontophoresis: Impact on skin integrity as evaluated by various methods. Crit Rev Ther Drug Carrier Syst, 25:381-401. (Pubitemid 351847207)
13. Sherertz EF, Sloan KB, McTiernan RG. (1987). Effect of skin pretreatment with vehicle alone or drug in vehicle on flux of a subsequently applied drug: Results of hairless mouse skin and diffusion cell studies. J Invest Dermatol, 89:249-52. (Pubitemid 17135368)
14. Costa P, Lobo J. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm, 13:123-33. (Pubitemid 32288781)
15. Guy RH, Hadgraft J, Hinz RS, Roskos KV, Bucks DAW. (1987). In vivo evaluations of transdermal drug delivery. In: Chien YW, ed. Transdermal controlled systemic medications. New York: Marcel Dekker Inc., 179-224.
16. Kim MK, Zhao H, Lee CH, Kim DD. (2001). Formulation of a reservoir-type testosterone transdermal delivery system. Int J Pharm, 219:51-9. (Pubitemid 32391364)
17. Pattnaik S, Swain K, Mallick S. (2009). Influence of polymeric system and loading dose on drug release from alfuzosin hydrochloride transdermal films. Lat Am J Pharm, 28:62-9.
18. Swain K, Pattnaik S, Mallick S, Chowdary KA. (2009). Influence of hydroxypropyl methylcellulose on drug release pattern of a gastroretentive floating drug delivery system using a 32 full factorial design. Pharm Dev Technol, 14:193-8.
19. Swain K, Pattnaik S, Sahu SC, Patnaik KK, Mallick S. (2010). Drug in adhesive type transdermal matrix systems of ondansetron hydrochloride: Optimization of permeation pattern using response surface methodology. J Drug Target, 18:106-14.
20. Lewis GA, Mathieu D, Phan-Tan-Luu R. (1999). Response surface methodology. In: Pharmaceutical experimental design. New York: Marcel Dekker Inc., 185-246.
21. Choi A, Gang H, Chun I, Gwak H. (2008). The effects of fatty acids in propylene glycol on the percutaneous absorption of alendronate across the excised hairless mouse skin. Int J Pharm, 357:126-31.
22. Ponec M, Haverkort M, Soei YL, Kempenaar J, Brussee H, Bodde HE. (1989). Toxicity screening of n-alkylazacycloheptan-2-one derivatives in cultured human skin cells: Structure-toxicity relationships. J Pharm Sci, 78:738-41. (Pubitemid 20101920)
23. Kadir R, Ponec M, Tiemessen HLGM, Junginger HE, Bodde HE. (1993). Oleyl surfactants as skin penetration enhancers: Effects on human stratum corneum permeability and in vitro toxicity to cultured human skin cells. In: Walters KA, Hadgraft J, eds. Pharmaceutical skin penetration enhancement, vol. 59. New York: Marcel Dekker, Inc., 215-28.
24. Barry BW. (1987). Mode of action of penetration enhancers in human skin. J Control Release, 6:85-97. (Pubitemid 18017724)
25. Cooper ER. (1984). Increased skin permeability for lipophilic molecules. J Pharm Sci, 73:1153-6. (Pubitemid 14055857)
26. Cooper ER, Merritt EW, Smith RL. (1985). Effect of fatty acids and alcohols on the penetration of acyclovir across human skin in vitro. J Pharm Sci, 74:688-9. (Pubitemid 15042137)
27. Aungst BJ, Rogers NJ, Shefter E. (1986). Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides. Int J Pharm, 33:225-34. (Pubitemid 17197807)
28. Nomura H, Fusao K, Sugimoto Y, Miyashita Y, Dohi M, Kato Y. (1990). Percutaneous absorption of indomethacin from mixtures of fatty alcohol and propylene glycol (FAPG base) through rat skin: Effects of oleic acid added to FAPG base. Chem Pharm Bull, 38:1421-4. (Pubitemid 20290852)
29. Myers RH, Montgomery DC. (2002). Response surface methodology: Process and product optimization using designed experiments. New York: John Wiley, 273-86.
30. Emami J (2006). In vitro-in vivo correlation: From theory to applications. J Pharm Pharm Sci, 9:31-51. (Pubitemid 43984046)